GlassScriptPhysician profile
Seyed M Alamian
NPI 1427067628
$2,186.25
in general payments reported to CMS, 2019-2025
31 companies · $553 in 2025
The $553 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $340 · 2021: $253 · 2022: $203 · 2023: $166 · 2024: $179 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $897.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $321.01 | 2019-2025 | Nucala, Trelegy Ellipta |
| Insmed, INC. | $287.83 | 2021-2025 | Arikayce, Brinsupri |
| Sunovion Pharmaceuticals INC. | $181.96 | 2019-2020 | |
| Abbvie INC. | $167.27 | 2023-2025 | Avycaz |
| Genentech USA, INC. | $155.71 | 2019-2023 | Xolair |
| Mallinckrodt Hospital Products INC. | $111.15 | 2021-2022 | |
| Intuitive Surgical, INC. | $105.85 | 2025 | |
| Genzyme Corporation | $102.52 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $97.21 | 2019-2025 | Symbicort |
| Novartis Pharmaceuticals Corporation | $76.31 | 2019-2023 | |
| Pulmonx Corporation | $50.43 | 2020-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.80 | 2019-2020 | |
| Allergan, INC. | $45.93 | 2020 | |
| Merck Sharp & Dohme LLC | $44.36 | 2021 | |
| Pfizer INC. | $42.88 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $36.41 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $34.79 | 2020 | |
| Masimo Corporation | $29.08 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.81 | 2025 | Glassia |
| Ani Pharmaceuticals, INC. | $23.32 | 2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $20.81 | 2025 | Zepbound |
| Harmony Biosciences LLC | $20.57 | 2022 | |
| Grifols USA, LLC | $19.96 | 2023 | Prolastin-C Liquid |
| Verona Pharma, INC. | $19.77 | 2025 | Ohtuvayre |
| Circassia INC. | $19.07 | 2020 | |
| Fisher & Paykel Healthcare INC | $18.73 | 2025 | Fisher & Paykel Healthcare |
| Bard Peripheral Vascular, INC. | $18.26 | 2019 | |
| Mylan Specialty L.P. | $16.46 | 2019 | |
| Amgen INC. | $15.70 | 2022 | |
| Shire North American Group INC | $15.00 | 2019 | |
| Phadia US INC. | $14.29 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seyed Alamian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.